AIM: Baicalein possesses several pharmacological activities including induction of apoptosis in human cancer cells; however, the mechanism is not fully understood. This study is to characterize baicalein-induced apoptosis and explore the underlying mechanism in human hepatoma cells. METHODS: Human hepatoma cell lines were treated with baicalein followed by cell number counting microscopically, flow cytometric analysis, TUNEL staining and DNA fragmentation assay. As for mechanistic studies, cells were incubated with baicalein and various inhibitors including Fas and caspases, or exogenous Bcl-2. The recovery of cells from apoptosis was then determined and calculated to delineate the baicalein-provoked apoptotic signaling. Factors involved in apoptosis were evaluated by Western blot for their potential involvement in the herbal medicine-induced cell death. RESULTS: Baicalein with different concentrations could trigger either partial S-phase arrest or apoptosis. Fas, with pro-apoptotic activity, was upregulated; and Bcl-X(subscript L) involved in anti-apoptotic pathway was downregulated in the cells challenged with baicalein. Application of the Fas-neutralizing antibody or overexpression of Bcl-2 prevented cells from baicalein-induced apoptosis. Caspase-2, -3, -8 and -9 were activated and engaged in mediating cell-killing cascades. CONCLUSION: Baicalein is capable of eliciting S-phase arrest at low concentrations and cell apoptosis at higher concentrations, and the latter is mediated by intrinsic and extrinsic pathways. The study may provide a molecular basis for the potential therapeutic use of baicalein in cancer treatment because of its multiple cell toxicities and underlying mechanisms.